According to GuruFocus Insider Data , these are the largest CFO buys during the past week. The overall trend of CFOs is illustrated in the chart below:
Opexa Therapeutics Inc. (OPXA, Financial): CFO Karthik Radhakrishnan Bought 50,000 Shares
CFO of Opexa Therapeutics Inc. (OPXA) Karthik Radhakrishnan bought 50,000 shares on 08/08/2013 at an average price of $1.5.
Opexa Therapeutics Inc. formerly known as Pharma was incorporated in Texas in March 1991 as a bio-pharmaceutical cmpany engaged in developing autologous personalized cellular therapies. Opexa Therapeutics Inc. has a market cap of $28.3619 million; its shares were traded at around $1.41 with and P/S ratio of 47.00.
On 8/14/2013 Opexa Therapeutics Inc. reported financial results for the quarter ended June 30, 2013 and provided an overview of recent corporate developments. Opexa reported revenue of $348,837 and $568,937 for the three and six months ended June 30, 2013, respectively. The revenue is related to the recognized portion of the $5 million upfront payment received from Merck Serono in conjunction with the February 2013 Option and License Agreement between Opexa and Merck Serono. The unearned revenue will be recognized over the expected term of Merck’s period to exercise its option to license Tcelna for multiple sclerosis. No revenues were recognized during the three and six months ended June 30, 2012.
CFO Karthik Radhakrishnan bought 50,000 shares of OPXA stock on 08/08/2013 at the average price of $1.5. Karthik Radhakrishnan owns at least 50,000 shares after this. The price of the stock has decreased by 6% since.
Anacor Pharmaceuticals Inc. (ANAC, Financial): Senior Vice President and CFO Geoffrey M. Parker Bought 50,000 Shares
Senior Vice President and CFO of Anacor Pharmaceuticals Inc. (ANAC) Geoffrey M. Parker bought 50,000 shares on 08/13/2013 at an average price of $8.34.
Anacor Pharmaceuticals Inc. was incorporated in the state of Delaware on Dec. 14, 2000. Anacor Pharmaceuticals Inc. has a market cap of $430.325 million; its shares were traded at around $10.86 with and P/S ratio of 35.03.
Aug. 8, 2013, Anacor Pharmaceuticals announced its financial results for the second quarter endedJune 30, 2013. Revenues for the quarter endedJune 30,2013 were$3.4 million, compared to$2.6 million for the comparable period in 2012. The increase in revenues from 2012 is primarily due to revenue for research services performed under the Gates Foundation Agreement.
Director Lucy Shapiro sold 20,000 shares of ANAC stock on 03/22/2013 at the average price of 6.91. Lucy Shapiro owns at least 333,664 shares after this. The price of the stock has increased by 57.16% since.
For the complete list of stocks that bought by their CFOs, go to: Insider Buys.
Opexa Therapeutics Inc. (OPXA, Financial): CFO Karthik Radhakrishnan Bought 50,000 Shares
CFO of Opexa Therapeutics Inc. (OPXA) Karthik Radhakrishnan bought 50,000 shares on 08/08/2013 at an average price of $1.5.
Opexa Therapeutics Inc. formerly known as Pharma was incorporated in Texas in March 1991 as a bio-pharmaceutical cmpany engaged in developing autologous personalized cellular therapies. Opexa Therapeutics Inc. has a market cap of $28.3619 million; its shares were traded at around $1.41 with and P/S ratio of 47.00.
On 8/14/2013 Opexa Therapeutics Inc. reported financial results for the quarter ended June 30, 2013 and provided an overview of recent corporate developments. Opexa reported revenue of $348,837 and $568,937 for the three and six months ended June 30, 2013, respectively. The revenue is related to the recognized portion of the $5 million upfront payment received from Merck Serono in conjunction with the February 2013 Option and License Agreement between Opexa and Merck Serono. The unearned revenue will be recognized over the expected term of Merck’s period to exercise its option to license Tcelna for multiple sclerosis. No revenues were recognized during the three and six months ended June 30, 2012.
CFO Karthik Radhakrishnan bought 50,000 shares of OPXA stock on 08/08/2013 at the average price of $1.5. Karthik Radhakrishnan owns at least 50,000 shares after this. The price of the stock has decreased by 6% since.
Anacor Pharmaceuticals Inc. (ANAC, Financial): Senior Vice President and CFO Geoffrey M. Parker Bought 50,000 Shares
Senior Vice President and CFO of Anacor Pharmaceuticals Inc. (ANAC) Geoffrey M. Parker bought 50,000 shares on 08/13/2013 at an average price of $8.34.
Anacor Pharmaceuticals Inc. was incorporated in the state of Delaware on Dec. 14, 2000. Anacor Pharmaceuticals Inc. has a market cap of $430.325 million; its shares were traded at around $10.86 with and P/S ratio of 35.03.
Aug. 8, 2013, Anacor Pharmaceuticals announced its financial results for the second quarter endedJune 30, 2013. Revenues for the quarter endedJune 30,2013 were$3.4 million, compared to$2.6 million for the comparable period in 2012. The increase in revenues from 2012 is primarily due to revenue for research services performed under the Gates Foundation Agreement.
Director Lucy Shapiro sold 20,000 shares of ANAC stock on 03/22/2013 at the average price of 6.91. Lucy Shapiro owns at least 333,664 shares after this. The price of the stock has increased by 57.16% since.
For the complete list of stocks that bought by their CFOs, go to: Insider Buys.
